SecBot SecBot

OCGN

Ocugen, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001372299 Biotech & Drug Discovery
$0.7730 −0.06 (−6.64%)
Nov 16 4:00 PM ET · prev $0.8280
Market cap
$296.4M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$10.50
+1258% · range $8.00–22.00
1 year
−33.4%
from $1.16 · Nov 17
30 days
−1.8%
from $0.7870
52-week range
$0.7030–2.48
−69% from high · low Oct 30
Avg volume 20D
7.56M
shares / day
Short interest
107.67M
≈31.7% of shares · +0.5%
Days to cover
16.4
at average volume
Insider net
−$1.1M
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 8 neutral oldest → newest, height = score
Avg score ·High conf. 6/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $25.8K at an average $1.23. 1 insider sold $1.1M. Price is 37% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 15 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +0.5% to 107.67M shares. 16.4 days to cover, ≈31.7% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGADD9,555,521$9.8M
MARSHALL WACE, LLPTRIM1,667,349$1.7M
BNP PARIBAS FINANCIAL MARKETSDOUBLED1,151,907$1.2M
MORGAN STANLEYADD608,327$626.6K
Quadrature Capital LtdDOUBLED597,565$615.5K
CITIGROUP INCTRIM255,119$262.8K
JPMORGAN CHASE & COADD227,832$248.3K
Creative PlanningDOUBLED231,890$238.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +1258%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 27, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

9 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$25.8K
bought · 1 insider
$1.1M
sold · 1 insider
−37.2%
vs their $1.23 cost
DateInsiderTypeValue
Oct 9, 2026
Musunuri Shankar
Chief Executive Officer
Oct 9, 2026
SELL$445.3K
Oct 9, 2026
Musunuri Shankar
Chief Executive Officer
Oct 9, 2026
SELL$54.4K
Sep 9, 2026
Musunuri Shankar
Chief Executive Officer
Sep 9, 2026
SELL$525.0K
Sep 9, 2026
Musunuri Shankar
Chief Executive Officer
Sep 9, 2026
SELL$64.1K
Jun 15, 2026
Johnson-Greene Treerita Essalima
Chief Financial Officer
Jun 15, 2026
BUY$25.8K
Jun 11, 2026
Coleman Blaise
Director
Jun 11, 2026
AWARD170,100 sh
Jun 11, 2026
Zhang Junge
Director
Jun 11, 2026
AWARD170,100 sh
Jun 11, 2026
Castillo Kirsten
Director
Jun 11, 2026
AWARD170,100 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.07-$0.08–-$0.06+12.5%$1.1M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
107,672,000
shares short
+0.5%
vs prior settlement
16.4
days to cover
≈31.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
T-90d Trial Readout: A Phase 3 Study Of OCU400 Gene Therapy for the Tre (Phase 3)
Trial: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa Sponsor: Ocu
Nov 10, 2026 SEC
Ocugen entered into an exclusive license agreement with Celairis Therapeutics for OCU400, a modifier gene therapy for…
8-K · Impact 4/10
Nov 10, 2026 Press
Ocugen granted Celairis exclusive rights to commercialize OCU400, its investigational gene therapy for retinitis…
Impact 4/10
Nov 6, 2026 SEC
Ocugen, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on November 6, 2026. The filing…
DEFA14A · Impact 2/10
Nov 6, 2026 SEC
Ocugen filed a DEFA14A notice postponing its reconvened special meeting to December 22, 2026, to vote on a proposal to…
DEFA14A · Impact 3/10
Oct 9, 2026 Insider
Musunuri Shankar sold 468,727 shares
Chief Executive Officer @ $0.9500 ($445.3K)
Oct 9, 2026 Insider
Musunuri Shankar sold 57,264 shares
Chief Executive Officer @ $0.9500 ($54.4K)
Sep 30, 2026 Inst.
UBS Group AG · ADD
9,555,521 shares ($9.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

17 filings · 6 press releases · 2 bullish · 0 bearish · 6 mixed · 9 neutral
All OCGN filing & press-release reports (23)